Physicians' Academy for Cardiovascular Education

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.

GLP-1RA reduces risk of MACE regardless of metformin use in T2DM

Sep. 29, 2021

EASD 2021 This analysis showed that semaglutide reduced the risk of MACE compared to placebo regardless of metformin use in patients with T2DM.

Differential associations of eGFR and UACR with CVD subtypes in patients with diabetes

News - Sep. 29, 2021
In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.

EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.

Improvements in two or more risk markers reduces risk of CVD and nephropathy in T2DM

News - Sep. 28, 2021

EASD 2021 This analysis showed that improvements in two or more risk markers were associated with reduced risk of expanded MACE, CV death and nephropathy in patients with T2DM.

CV and renal outcomes reduced by nonsteroidal MRA in T2DM across spectrum of kidney disease

News - Aug. 28, 2021

ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD
Kevin Damman discusses the results of the FIGARO-DKD trial which compared the non-steroidal MRA finerenone with placebo in patients with diabetes and chronic kidney disease.

ESC 2021 Kevin Damman discusses the results of the FIGARO-DKD trial which compared the nonsteroidal MRA finerenone with placebo in patients with diabetes and chronic kidney disease.

Nonsteroidal MRA reduces risk of CV outcomes in patients with T2DM and mild-to-moderate CKD

News - Aug. 28, 2021

ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.

Individuals with ‘Metabolically healthy obesity’ are actually not healthy

Literature - Aug. 16, 2021 - Zhou Z et al. - Diabetologia. 2021

This study showed that individuals with metabolically healthy obesity were at higher risk of diabetes, ASCVD, HF, respiratory diseases and all-cause mortality, compared with people with metabolically healthy non-obesity.

Prevalence of diabetes among US adults increased significantly from 1999 to 2018

Literature - Aug. 3, 2021 - Li Wang et al. - JAMA. 2021

This study showed that estimated age-standardized prevalence of diabetes among US adults increased significantly from 9.8% in 1999-2000 to 14.3% in 2017-2018. In 2015-2018, only 21.2% of adults with diagnosed diabetes achieved individualized HbA1C targets, BP <130/80 mmHg, and LDL-c <100 mg/dL.

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.